Drugs derived from phage display from candidate identification to clinical practice

mAbs

Volumn 6, Issue 1, 2014, Pages 73-85

  Nixon, Andrew E ^a   Sexton, Daniel J ^a   Ladner, Robert C ^a  

^a Dyax Corp   (United States)

Author keywords

Antibodies; Biologics; Clinical trials; Drug discovery; Peptides; Phage display

Indexed keywords

ADALIMUMAB; BELIMUMAB; ECALLANTIDE; NECITUMUMAB; RAMUCIRUMAB; RANIBIZUMAB; RAXIBACUMAB; RECOMBINANT BLOOD CLOTTING FACTOR 8; ROMIPLOSTIM; TREBANANIB;

ARTICLE; CLINICAL PRACTICE; HUMAN; IMMUNOLOGICAL TOLERANCE; PHAGE DISPLAY;

ANIMALS; DRUG DISCOVERY; HUMANS; SINGLE-CHAIN ANTIBODIES;

EID: 84892591532     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27240     Document Type: Article

References (90)

1. Drews J. Drug discovery: a historical perspective. Science 2000; 287:1960-4; PMID:10720314; http:// dx.doi.org/10.1126/science.287.5460.1960 (Pubitemid 30158662)
2. Bradbury AR, Sidhu S, Dübel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 2011; 29:245-54; PMID:21390033; http://dx.doi.org/10.1038/ nbt.1791
3. Buckler DR, Schofield D, Sexton DJ, Lowe D, Vaughan TJ. Selection and Screening of Antibody Phage Display Libraries. In: Wood CR, ed. Antibody Drug Discovery. London: Imperial College Press, 2012.
4. Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996; 35:8058-67; PMID:8672510; http://dx.doi.org/10.1021/bi952629y (Pubitemid 26202548)
5. Markland W, Ley AC, Lee SW, Ladner RC. Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Biochemistry 1996; 35:8045-57; PMID:8672509; http://dx.doi. org/10.1021/bi9526286 (Pubitemid 26202547)
6. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-7; PMID:4001944; http://dx.doi.org/10.1126/science.4001944 (Pubitemid 15000355)
7. Guterman S, Kent RB, Ladner R, Ley A, Markland W, Roberts BL. Direct evolution of novel binding proteins. US Patent 5223409A. Protein Engineering Corp., Mar 1, 1991.
8. Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des 2010; 16:1040-54; PMID:20030617; http://dx.doi. org/10.2174/138161210790963788
9. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552-4; PMID:2247164; http://dx.doi. org/10.1038/348552a0 (Pubitemid 120015109)
10. Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods 2004; 290:29-49; PMID:15261570; http://dx.doi.org/10.1016/j. jim.2004.04.007 (Pubitemid 38917129)
11. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218-30; PMID:10373423; http://dx.doi.org/10.1074/jbc.274.26.18218
12. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, Rem L, Frans N, Daukandt M, Pieters H, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining- region diversity. Nat Biotechnol 2005; 23:344-8; PMID:15723048; http://dx.doi.org/10.1038/nbt1067 (Pubitemid 41094423)
13. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large nonimmunized phage display library. Nat Biotechnol 1996; 14:309-14; PMID:9630891; http://dx.doi. org/10.1038/nbt0396-309
14. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86; PMID:10656818; http://dx.doi.org/10.1006/ jmbi.1999.3444
15. Rothe C, Urlinger S, Löhning C, Prassler J, Stark Y, Jäger U, Hubner B, Bardroff M, Pradel I, Boss M, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008; 376:1182-200; PMID:18191144; http://dx.doi.org/10.1016/j. jmb.2007.12.018
16. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009; 69:1517-26; PMID:19208838; http://dx.doi.org/10.1158/0008-5472.CAN-08- 3255
17. Brockmann EC, Cooper M, Strömsten N, Vehniäinen M, Saviranta P. Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J Immunol Methods 2005; 296:159-70; PMID:15680160; http://dx.doi.org/10.1016/j.jim.2004.11.008 (Pubitemid 40174749)
18. Zani ML, Moreau T. Phage display as a powerful tool to engineer protease inhibitors. Biochimie 2010; 92:1689-704; PMID:20470858; http://dx.doi. org/10.1016/j.biochi.2010.05.003
19. Beste G, Schmidt FS, Stibora T, Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A 1999; 96:1898-903; PMID:10051566; http:// dx.doi.org/10.1073/ pnas.96.5.1898 (Pubitemid 29117839)
20. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23:1257-68; PMID:16211069; http://dx.doi.org/10.1038/nbt1127 (Pubitemid 41486853)
21. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245-55; PMID:19501012; http://dx.doi.org/10.1016/j.cbpa.2009.04.627
22. Reichert JM. Which are the antibodies to watch in 2012? MAbs 2012; 4:1-3; PMID:22327425; http:// dx.doi.org/10.4161/mabs.4.1.18719
23. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http:// dx.doi.org/10.4161/mabs.22976
24. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837
25. HUMIRA [package insert]. Abbott Park, Il: Abbott Laboratories, 2012.
26. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) 1994; 12:899-903; PMID:7521646; http://dx.doi. org/10.1038/nbt0994-899
27. Salfeld JG, Allen DJ, Hoogenboom HRJM, Kaymakcalan Z, Labkovsky B, Mankovich JA, et al. Human antibodies that bind human TNF?. US Patent 6090382. US BASF Aktiengesellschaft, Germany, Feb 9, 1996.
28. Pharmacology Review(s): Adalimumab (BLA 125057/0). 2002.
29. Stohl W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 2012; 14:303-9; PMID:22547203; http://dx.doi.org/10.1007/ s11926-012-0254-6
30. Pharmacology Review(s): Belimumab (BLA 125370). 2011.
31. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48:3253-65; PMID:14613291; http://dx.doi.org/10.1002/ art.11299 (Pubitemid 37409340)
32. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, et al.; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918-30; PMID:22127708; http://dx.doi. org/10.1002/art.30613
33. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62:201-10; PMID:20039404; http://dx.doi. org/10.1002/art.27189
34. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71:1833-8; PMID:22550315; http://dx.doi.org/10.1136/ annrheumdis-2011-200831
35. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet 2011; 377:721-31; PMID:21296403; http://dx.doi.org/10.1016/ S0140-6736(10)61354-2
36. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, et al.; BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64:2328-37; PMID:22275291; http://dx.doi. org/10.1002/art.34400
37. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71:1343-9; PMID:22337213; http://dx.doi.org/10.1136/ annrheumdis-2011-200937
38. Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, et al.; LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64:3364-73; PMID:22674457; http://dx.doi.org/10.1002/ art.34564
39. Stolz LE, Horn PT. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema. Drugs Today (Barc) 2010; 46:547-55; PMID:20830315; http://dx.doi.org/10.1358/ dot.2010.46.8.1507205
40. Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101:279-86; PMID:18814451; http://dx.doi. org/10.1016/S1081-1206(10)60493-0
41. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angiooedema. Lancet 1998; 351:1693-7; PMID:9734886; http://dx.doi.org/10.1016/S0140-6736(97)09137-X
42. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77:2660-7; PMID:1710516
43. Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 2010; 6:29-39; PMID:20383888; http://dx.doi.org/10.1586/ eci.09.60
44. KALBITOR (ecallantide) [package insert]. In: Corp. D, ed. Burlington, MA: Dyax Corp., 2012.
45. Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996; 35:8058-67; PMID:8672510; http://dx.doi.org/10.1021/bi952629y (Pubitemid 26202548)
46. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29:255-8; PMID:14572818; http://dx.doi.org/10.1016/ S1473-0502(03)00170-8 (Pubitemid 37315589)
47. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276:1696-9; PMID:9180079; http://dx.doi.org/10.1126/science.276.5319.1696 (Pubitemid 27421976)
48. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010; 150:9-20; PMID:20298251
49. Shimamoto G, Gegg C, Boone T, Quéva C. Peptibodies: A flexible alternative format to antibodies. MAbs 2012; 4:586-91; PMID:22820181; http:// dx.doi.org/10.4161/mabs.21024
50. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395-403; PMID:18242413; http://dx.doi.org/ 10.1016/S0140-6736(08)60203-2 (Pubitemid 351181334)
51. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161-71; PMID:18981291; http://dx.doi.org/10. 1182/ blood-2008-04-150078
52. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, et al. AMG 531, a thrombopoiesisstimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-81; PMID:17050891; http://dx.doi. org/10.1056/NEJMoa054626 (Pubitemid 44583957)
53. Burns DL. Licensure of vaccines using the Animal Rule. Curr Opin Virol 2012; 2:353-6; PMID:22709520; http://dx.doi.org/10.1016/j. coviro.2012.01.004
54. Raxibacumab MS. MAbs 2009; 1:531-8; PMID:20068396; http://dx.doi.org/10. 4161/ mabs.1.6.10195
55. Huang JX, Bishop-Hurley SL, Cooper MA. Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother 2012; 56:4569-82; PMID:22664969; http://dx.doi.org/10.1128/ AAC.00567-12
56. Froude JW 2nd, Thullier P, Pelat T. Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) 2011; 3:1433-52; PMID:22174979; http://dx.doi.org/10.3390/ toxins3111433
57. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135-44; PMID:19587338; http://dx.doi.org/10.1056/ NEJMoa0810603
58. Demidova-Rice TN, Hamblin MR, Herman IM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care 2012; 25:349-70; PMID:22820962; http://dx.doi.org/10.1097/01. ASW.0000418541.31366.a3
59. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013; 120:106-14; PMID:23031671; http://dx.doi.org/10.1016/j. ophtha.2012.07.038
60. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013; 273:114-27; PMID:23216836; http://dx.doi.org/10.1111/ joim.12019
61. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9; PMID:9377574 (Pubitemid 27441066)
62. Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol 2008:131-50.
63. Baca M, Presta LG, O'Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem 1997; 272:10678-84; PMID:9099717; http:// dx.doi.org/10.1074/jbc.272.16.10678 (Pubitemid 27181078)
64. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293:865-81; PMID:10543973; http://dx.doi.org/10.1006/ jmbi.1999.3192 (Pubitemid 29527672)
65. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27:536-44; PMID:10528633; http://dx.doi.org/10.1177/ 019262339902700507 (Pubitemid 29446822)
66. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46:726-33; PMID:15671306; http://dx.doi.org/10.1167/ iovs.04-0601 (Pubitemid 40270359)
67. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31; PMID:17021318; http://dx.doi.org/10.1056/ NEJMoa054481 (Pubitemid 44511557)
68. LUCENTIS Label. San Francisco, CA: Genentech, 2006.
69. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-16; PMID:15542434; http://dx.doi.org/10.1016/j. ccr.2004.09.030 (Pubitemid 39469986)
70. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27:3557-65; PMID:19546406; http://dx.doi.org/10.1200/ JCO.2008.19.6683
71. Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, et al. Phase II randomized, double-blind, placebocontrolled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 2013; 24:710-8; PMID:23108953; http:// dx.doi.org/10.1093/annonc/mds502
72. Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013; 108:503-11; PMID:23361051; http:// dx.doi.org/10.1038/bjc.2012. 594
73. Liu M, Zhu Z. Human anti-epidermal growth factor receptor antibody. US Patent 7598350.: ImClone LLC, March 21, 2005.
74. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. Molecular determinants of epidermal growth factor binding: a molecular dynamics study. PLoS One 2013; 8:e54136; PMID:23382875; http://dx.doi. org/10.1371/journal.pone.0054136
75. Dantas-Barbosa C, de Macedo Brigido M, Maranhao AQ. Antibody phage display libraries: contributions to oncology. Int J Mol Sci 2012; 13:5420-40; PMID:22754305; http://dx.doi.org/10.3390/ ijms13055420
76. Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011; 11:1223-31; PMID:21679088; http://dx.doi.org/10.1517/ 14712598.2011.595709
77. Zhu Z. Human antibodies specific to KDR and uses therof. US Patent 7498414 B2. US: Imclone Systems Incorporated, March 4, 2003.
78. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780-7; PMID:20048182; http://dx.doi.org/10.1200/JCO.2009.23.7537
79. Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003; 17:604-11; PMID:12646950; http://dx.doi.org/10.1038/sj.leu.2402831 (Pubitemid 36395655)
80. Vacchelli E, Eggermont A, Galon J, Saut?s-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/ onci.22789
81. Kelley BD, Booth J, Tannatt M, Wub QL, Ladner R, Yuc J, Potter D, Ley A. Isolation of a peptide ligand for affinity purification of factor VIII using phage display. J Chromatogr A 2004; 1038:121-30; PMID:15233528; http://dx.doi.org/10.1016/j. chroma.2004.03.041 (Pubitemid 38624360)
82. Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia 2010; 16:717-25; PMID:20041957; http://dx.doi.org/10.1111/j.1365-2516.2009.02160.x
83. Krumpe LR, Mori T. Potential of phage-displayed peptide library technology to identify functional targeting peptides. Expert Opin Drug Discov 2007; 2:525; PMID:20150977; http://dx.doi. org/10.1517/17460441.2.4.525
84. Finlay WJ, Bloom L, Cunningham O. Phage display: a powerful technology for the generation of high specificity affinity reagents from alternative immune sources. Methods Mol Biol 2011; 681:87-101; PMID:20978962; http://dx.doi. org/10.1007/978-1-60761-913-0-6
85. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv 2010; 28:849-58; PMID:20659548; http://dx.doi.org/10.1016/j.biotechadv.2010.07.004
86. Spencer S, Bethea D, Raju TS, Giles-Komar J, Feng Y. Solubility evaluation of murine hybridoma antibodies. MAbs 2012; 4:319-25; PMID:22531448; http:// dx.doi.org/10.4161/mabs.19869
87. Jacobs SA, Wu SJ, Feng Y, Bethea D, O'Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 2010; 27:65-71; PMID:19911257; http://dx.doi.org/10.1007/ s11095-009-0007-z
88. Conley GP, Viswanathan M, Hou Y, Rank DL, Lindberg AP, Cramer SM, Ladner RC, Nixon AE, Chen J. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability. Biotechnol Bioeng 2011; 108:2634-44; PMID:21618474; http://dx.doi. org/10.1002/bit.23220
89. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 2010; 19:954-66; PMID:20198683
90. Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 2010; 23:643-51; PMID:20543007; http://dx.doi. org/10.1093protein/gzq037